Show simple item record

dc.contributor.authorGotham, D
dc.contributor.authorMcKenna, L
dc.contributor.authorDeborggraeve, S
dc.contributor.authorMadoori, S
dc.contributor.authorBranigan, D
dc.date.accessioned2021-09-14T02:19:26Z
dc.date.available2021-09-14T02:19:26Z
dc.date.issued2021-08-31
dc.identifier.pmid34464413
dc.identifier.doi10.1371/journal.pone.0256883
dc.identifier.urihttp://hdl.handle.net/10144/619985
dc.description.abstractBackground: The GeneXpert diagnostic platform from the US based company Cepheid is an automated molecular diagnostic device that performs sample preparation and pathogen detection within a single cartridge-based assay. GeneXpert devices can enable diagnosis at the district level without the need for fully equipped clinical laboratories, are simple to use, and offer rapid results. Due to these characteristics, the platform is now widely used in low- and middle-income countries for diagnosis of diseases such as TB and HIV. Assays for SARS-CoV-2 are also being rolled out. We aimed to quantify public sector investments in the development of the GeneXpert platform and Cepheid's suite of cartridge-based assays. Methods: Public funding data were collected from the proprietor company's financial filings, grant databases, review of historical literature concerning key laboratories and researchers, and contacting key public sector entities involved in the technology's development. The value of research and development (R&D) tax credits was estimated based on financial filings. Results: Total public investments in the development of the GeneXpert technology were estimated to be $252 million, including >$11 million in funding for work in public laboratories leading to the first commercial product, $56 million in grants from the National Institutes of Health, $73 million from other U.S. government departments, $67 million in R&D tax credits, $38 million in funding from non-profit and philanthropic organizations, and $9.6 million in small business 'springboard' grants. Conclusion: The public sector has invested over $250 million in the development of both the underlying technologies and the GeneXpert diagnostic platform and assays, and has made additional investments in rolling out the technology in countries with high burdens of TB. The key role played by the public sector in R&D and roll-out stands in contrast to the lack of public sector ability to secure affordable pricing and maintenanceen_US
dc.language.isoenen_US
dc.publisherPublic Library of Scienceen_US
dc.titlePublic investments in the development of GeneXpert molecular diagnostic technology.en_US
dc.typeOther
dc.typeArticle
dc.typeOther
dc.identifier.eissn1932-6203
dc.identifier.journalPloS oneen_US
dc.source.journaltitlePloS one
dc.source.volume16
dc.source.issue8
dc.source.beginpagee0256883
dc.source.endpage
refterms.dateFOA2021-09-14T02:19:27Z
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Gotham et al 2021 Public inves ...
Size:
1.011Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record